aTyr Pharma to Present at 34th Annual J.P. Morgan Healthcare Conference

Jan 07, 2016, 07:30 ET from aTyr Pharma, Inc.

SAN DIEGO, Jan. 7, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced the Company's participation at the 34th Annual J.P. Morgan Healthcare Conference to be held at the Westin St. Francis in San Francisco, CA from January 11 – 14, 2016.

John Mendlein, Ph.D., aTyr's CEO, will provide an overview of the Company during a presentation at 10:30 a.m. PT on Wednesday, January 13, 2016.  The presentation will be webcast live through the "Investors" section of the aTyr Pharma website at www.atyrpharma.com.  An audio replay will be available for 30 days following the initial presentation webcast. 

About aTyr Pharma

aTyr Pharma is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of Physiocrine biology, a newly discovered set of physiological modulators. The Company's lead candidate, Resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. Resolaris is currently in a Phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (FSHD); a Phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (LGMD) 2B or FSHD; and a Phase 1b/2 trial in patients with an early onset form of FSHD.  An initial trial is planned in rare pulmonary diseases with an immune component (RPIC) in patients with interstitial lung disease (ILD). To protect this pipeline, aTyr built an intellectual property estate comprising 54 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by aTyr. aTyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation for which there are currently limited or no treatment options. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute. For more information, please visit http://www.atyrpharma.com.

SOURCE aTyr Pharma, Inc.



RELATED LINKS

http://www.atyrpharma.com